Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Signore

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|September 7, 2018
Renal cancer: new models and approach for personalizing therapySimona di Martino, Gabriele De Luca, Ludovica Grassi, et al.
Cell Death & Disease|March 1, 2019
Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseasesLudovica Grassi, Romina Alfonsi, Federica Francescangeli, et al.
Gut|January 13, 2021
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cellsLaura Rosa Mangiapane, Annalisa Nicotra, Alice Turdo, et al.
Cell Death & Disease|June 22, 2021
Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancerMichele Signore, Romina Alfonsi, Giulia Federici, et al.
Cell Death & Disease|July 24, 2019
A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumorsIsabella Orienti, Federica Francescangeli, Maria Laura De Angelis, et al.
Cell Death & Disease|June 1, 2026
Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivoMatteo Cassandri, Antonella Porrazzo, Simona Camero, et al.
Cell Death and Differentiation|February 3, 2021
Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51Gwenola Manic, Martina Musella, Francesca Corradi, et al.
Gut|April 9, 2017
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cellsGwenola Manic, Michele Signore, Antonella Sistigu, et al.
Cell Death Discovery|August 6, 2024
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaksMatteo Cassandri, Antonella Porrazzo, Silvia Pomella, et al.
Science (New York, N.Y.)|October 31, 2015
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1Erika Vacchelli, Yuting Ma, Elisa E Baracco, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Journal of Experimental & Clinical Cancer Research : CR|September 7, 2018
Renal cancer: new models and approach for personalizing therapySimona di Martino, Gabriele De Luca, Ludovica Grassi, et al.
Cell Death & Disease|March 1, 2019
Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseasesLudovica Grassi, Romina Alfonsi, Federica Francescangeli, et al.
Gut|January 13, 2021
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cellsLaura Rosa Mangiapane, Annalisa Nicotra, Alice Turdo, et al.
Cell Death & Disease|June 22, 2021
Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancerMichele Signore, Romina Alfonsi, Giulia Federici, et al.
Cell Death & Disease|July 24, 2019
A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumorsIsabella Orienti, Federica Francescangeli, Maria Laura De Angelis, et al.
Cell Death & Disease|June 1, 2026
Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivoMatteo Cassandri, Antonella Porrazzo, Simona Camero, et al.
Cell Death and Differentiation|February 3, 2021
Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51Gwenola Manic, Martina Musella, Francesca Corradi, et al.
Gut|April 9, 2017
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cellsGwenola Manic, Michele Signore, Antonella Sistigu, et al.
Cell Death Discovery|August 6, 2024
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaksMatteo Cassandri, Antonella Porrazzo, Silvia Pomella, et al.
Science (New York, N.Y.)|October 31, 2015
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1Erika Vacchelli, Yuting Ma, Elisa E Baracco, et al.
Pageof 7